Clinical Trials Logo

Clinical Trial Summary

The goal of this single blind randomized controlled trial is to investigate the effect of sensory-perception-motor training on cognitive functions, balance and gait in patients with Parkinson's Disease? The main questions it aims to answer are: - Does sensory-perception-motor training have an effect on balance in patients with Parkinson's Disease? - Does sensory-perception-motor training have an effect on cognitive functions in patients with Parkinson's Disease? - Does sensory-perception-motor training have an effect on gait in patients with Parkinson's Disease? Patients in the control group will be asked to continue their routine lives and return for evaluation after 8 weeks. Individuals in the control group will be followed without any additional treatment or advice. Patients in the study group will receive sensory-perceptual-motor training for 60 minutes, 3 days a week for 8 weeks, in addition to their routine lives. No additional recommendations will be given to individuals in either group.


Clinical Trial Description

30 patients will be included in the study. Patients who agree to participate in the study will be divided into two groups, study and control groups, by using a table of random numbers, ensuring that there are equal numbers of patients in each group. Demographic and clinical information of all patients participating in the study will be recorded. Montreal Cognitive Assessment Test and Modified Hoehn Yahr Staging Scale scores of all participants will be recorded by the neurologist and eligible patients will be included in the study. Evaluations to be applied to the groups within the scope of the study: Unified Parkinson's Disease Rating Scale Part 3 , Static posturography measurement, Functional Reaching Test , Dynamic Gait Index , Rapid Mild Cognitive Impairment Screening, Stroop Test, Symbol Digit Modalities Test , Clock Drawing Test. Assessments will be made during the patients' "on" period (approximately 60 minutes after medication intake). On the first day of the study, demographic information will be recorded in both groups and the patients participating in the study will be randomized. After randomization, patients in the control group will be asked to continue their routine lives and return for evaluation after 8 weeks. Individuals in the control group will be followed without any additional treatment or advice. Patients in the study group will receive sensory-perceptual-motor training for 60 minutes, 3 days a week for 8 weeks, in addition to their routine lives. No additional recommendations will be given to individuals in either group. Patients will be excluded from the study if they participate in any physiotherapy and rehabilitation program during the study. Patients in the study group will be evaluated 3 times in total, at the beginning of the study, at the end of the study (in the 8th week) and 4 weeks after the end of the study (in the 12th week), and patients in the control group will be evaluated 2 times in total, at the beginning of the study and in the 8th week. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06390163
Study type Interventional
Source Hacettepe University
Contact Büsra Seçkinogullari Korkusuz, MSc
Phone 05442436914
Email busra.seckinogullari@hacettepe.edu.tr
Status Recruiting
Phase N/A
Start date January 5, 2024
Completion date November 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05103618 - Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA Phase 2
Completed NCT03700684 - Voice Treatment for Parkinson's Disease N/A
Completed NCT04202757 - Intravenous Plasma Treatment for Parkinson's Disease Early Phase 1
Completed NCT05027620 - Feasibility of Motor-cognitive Home Training for Parkinson's Disease Using eHealth Technology N/A
Completed NCT03652363 - GDNF in ideopathicParkinsons Disease Phase 2
Recruiting NCT02960464 - tDCS for Treatment of Depression in Parkinson's Disease N/A
Completed NCT05699161 - Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson Phase 1/Phase 2
Completed NCT03944785 - Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
Completed NCT01227265 - Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037) Phase 3
Terminated NCT01215227 - An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153) Phase 3
Withdrawn NCT05832775 - Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's Phase 1
Active, not recruiting NCT02780895 - Parkinsonian Brain Repair Using Human Stem Cells Phase 1
Recruiting NCT01860794 - Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease Phase 1/Phase 2
Terminated NCT02393027 - Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999 Early Phase 1
Completed NCT02373072 - A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease Phase 1
Completed NCT02445651 - Physiological Effects of Nutritional Support in Patients With Parkinson's Disease N/A
Completed NCT00437125 - Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease Phase 4
Completed NCT02723396 - Sleep, Awake & Move - Part I
Completed NCT00599339 - Transdermal Rotigotine User Surveillance Study
Suspended NCT05471609 - Sustained Release Oral Formulation for Treatment of Parkinson's Disease Early Phase 1